Filana Therapeutics
FLNA
140 hedge funds and large institutions have $215M invested in Filana Therapeutics in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 25 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
11% more call options, than puts
Call options by funds: $65.2M | Put options by funds: $58.7M
2.81% more ownership
Funds ownership: 28.02% → 30.83% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 152 → 140 (-12)
25% less capital invested
Capital invested by funds: $287M → $215M (-$71.4M)
36% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$8.88M |
| 2 |
Morgan Stanley
New York
|
+$5.19M |
| 3 |
SC
Sculptor Capital
New York
|
+$4.46M |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$3.38M |
| 5 |
SG Americas Securities
New York
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.15M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.84M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.16M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$968K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$910K |
FLNA Hedge Fund Activity: Q3 2023 in Review
140 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q3 2023, worth a combined $215M — down 25% from $287M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of FLNA and 16 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 55 added.
The largest buyer was Bank of America, adding an estimated $8.88M. The largest seller was Susquehanna International Group, cutting an estimated $3.15M.
- 140 institutional investors held Filana Therapeutics (FLNA) as of Q3 2023, down from 152 in Q2 2023.
- Funds reported $215M of Filana Therapeutics stock for Q3 2023, down 25% quarter-over-quarter.
- 16 funds opened new Filana Therapeutics positions in Q3 2023 and 25 closed out, a net change of -9 holders.
- The largest Filana Therapeutics buyer in Q3 2023 was Bank of America, an estimated $8.88M added.
- The largest Filana Therapeutics seller in Q3 2023 was Susquehanna International Group, an estimated $3.15M sold.
Based on aggregated 13F filings for Q3 2023.